Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Breast 4CNS 1

Conditions

Breast Neoplasms 1316Triple Negative Breast Neoplasms 233Ovarian Neoplasms 115Carcinoma, Non-Small-Cell Lung 89Colorectal Neoplasms 86Neoplasm Metastasis 83Prostatic Neoplasms 79Neoplasms 76Lung Neoplasms 70Melanoma 57Pancreatic Neoplasms 54Endometrial Neoplasms 54Stomach Neoplasms 49Uterine Cervical Neoplasms 44Carcinoma, Intraductal, Noninfiltrating 41Squamous Cell Carcinoma of Head and Neck 38Colonic Neoplasms 37Head and Neck Neoplasms 33Carcinoma, Renal Cell 33Esophageal Neoplasms 27Breast Carcinoma In Situ 27Small Cell Lung Carcinoma 25Sarcoma 25Brain Neoplasms 25Urinary Bladder Neoplasms 22Anatomic Stage I Breast Cancer AJCC v8 22Carcinoma, Transitional Cell 20Advanced Breast Cancer 18Liver Neoplasms 17Gastrointestinal Neoplasms 17

Interventions

tucatinib 1pertuzumab 1atezolizumab 1Trastuzumab 1Fulvestrant 1Alpelisib 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
HER2-positive Metastatic Breast Cancer × Breast × 90 days × Clear all
NCT06595563 2026-05-07

ZEPHIR-02

Jules Bordet Institute

Phase 2 Recruiting
87 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

NCT06551116 2026-04-07

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Abramson Cancer Center at Penn Medicine

Recruiting
200 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Criterium, Inc.

Phase 1/2 Active not recruiting
40 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡